AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

by Barry101 | Sep 8, 2021 | Press Release, Uncategorized

OCALA, Fla., Sept. 08, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a...

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

by Barry101 | Aug 25, 2021 | Press Release, Uncategorized

Patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program have reported consistent improvements in cognitive functionOCALA, Fla., Aug. 25, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on...

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

by Barry101 | Aug 25, 2021 | Press Release, Uncategorized

Patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program have reported consistent improvements in cognitive functionOCALA, Fla., Aug. 25, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on...

AIM ImmunoTech Provides Second Quarter 2021 Business Update

by Barry101 | Aug 17, 2021 | Press Release, Uncategorized

OCALA, Fla., Aug. 17, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.    Second Quarter 2021 Financial Highlights: As of June 30, 2021, AIM had cash,...

AIM ImmunoTech Provides Second Quarter 2021 Business Update

by Barry101 | Aug 17, 2021 | Press Release, Uncategorized

OCALA, Fla., Aug. 17, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.    Second Quarter 2021 Financial Highlights: As of June 30, 2021, AIM had cash,...

AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

by Barry101 | Aug 16, 2021 | Press Release, Uncategorized

BioFlorida is the State’s Leading Life Sciences Industry AssociationOCALA, Fla., Aug. 16, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the...